<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="Pilocarpine" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">livertox</book-id>
    <book-title-group>
      <book-title>LiverTox</book-title>
      <subtitle>Clinical and Research Information on Drug-Induced Liver Injury</subtitle>
    </book-title-group>
    <pub-date date-type="pubr" publication-format="electronic">
      <year>2012</year>
    </pub-date>
    <publisher>
      <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
      <publisher-loc>Bethesda (MD)</publisher-loc>
    </publisher>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">Pilocarpine</book-part-id>
      <title-group>
        <title>Pilocarpine</title>
      </title-group>
      <pub-history>
        <date date-type="updated">
          <day>24</day>
          <month>6</month>
          <year>2020</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="livertox">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury</related-object>
      <related-object link-type="previous-part-link" source-id="livertox" document-id="PDE5Inhibitors" document-type="chapter">Phosphodiesterase Type 5 (PDE5) Inhibitors</related-object>
      <related-object link-type="next-part-link" source-id="livertox" document-id="Pimavanserin" document-type="chapter">Pimavanserin</related-object>
    </book-part-meta>
    <body>
      <sec id="Pilocarpine.OVERVIEW">
        <title>OVERVIEW</title>
        <sec id="Pilocarpine.Introduction" sec-type="pubmed-excerpt">
          <title>Introduction</title>
          <p>Pilocarpine is an orally available cholinergic agonist that is used to treat symptoms of dry mouth in patients with keratoconjunctivitis sicca (Sj&#x000f6;gren syndrome) or with xerostomia (dry mouth) due to local irradiation. Pilocarpine has not been linked to serum enzyme elevations during therapy or to instances of clinically apparent liver injury.</p>
        </sec>
        <sec id="Pilocarpine.Background">
          <title>Background</title>
          <p>Pilocarpine (pye" loe kar' peen) is a cholinergic agonist that stimulates muscarinic receptors, resulting in an increase in parasympathetic activity. Engagement of the cholinergic receptors causes increased secretion from exocrine glands, including sweat, salivary, lacrimal, gastric, pancreatic and intestinal glands, as well as increased tone and motility of smooth muscle cells in the eye, respiratory and gastrointestinal tract. Use of daily oral doses of pilocarpine has been shown to improve symptoms of dry mouth and increase salivary flow in patients with Sj&#x000f6;gren syndrome and with xerostomia due to local irradiation therapy. Pilocarpine for oral use was approved for use in the United States in the 1990s and is currently available in generic forms as tablets of 5 mg. Pilocarpine is also available as ophthalmologic drops for therapy of glaucoma and ocular hypertension. The typical oral dose is 5 mg 2 to 4 times daily. Side effects are usually mild and largely attributable to cholinergic stimulation including increased sweating, rhinitis, nausea, diarrhea, headaches, dizziness, visual disturbances and fatigue.</p>
        </sec>
        <sec id="Pilocarpine.Hepatotoxicity">
          <title>Hepatotoxicity</title>
          <p>In clinical trials of pilocarpine, serum enzyme elevations were uncommon and no more frequent than with placebo. Despite, wide scale use, there have been no published reports of acute liver injury attributable to pilocarpine.</p>
        </sec>
        <sec id="Pilocarpine.Mechanism_of_Injury">
          <title>Mechanism of Injury</title>
          <p>The mechanism by which pilocarpine might cause serum aminotransferase elevations is not known. Pilocarpine is metabolized in parasympathetic synaptic clefts and in plasma and has little hepatic metabolism.</p>
          <p>Drug Class: Sj&#x000f6;gren Syndrome Agents, Cholinergic Agents</p>
          <p>Other Drugs in the Class: <related-object link-type="booklink" source-id="livertox" document-id="Cevimeline" document-type="chapter">Cevimeline</related-object></p>
        </sec>
      </sec>
      <sec id="Pilocarpine.PRODUCT_INFORMATION">
        <title>PRODUCT INFORMATION</title>
        <p>
          <bold>REPRESENTATIVE TRADE NAMES</bold>
        </p>
        <p>Pilocarpine &#x02013; Generic</p>
        <p>
          <bold>DRUG CLASS</bold>
        </p>
        <p>Sj&#x000f6;gren Syndrome Agents</p>
        <p>
          <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?label=all&#x00026;query=Pilocarpine">COMPLETE LABELING</ext-link>
        </p>
        <p>Product labeling at DailyMed, National Library of Medicine, NIH</p>
      </sec>
      <sec id="Pilocarpine.CHEMICAL_FORMULA_AND_STRUCTU">
        <title>CHEMICAL FORMULA AND STRUCTURE</title>
        <table-wrap id="Pilocarpine.Tc" orientation="portrait" position="anchor">
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_Pilocarpine.Tc_1_1_1_1" valign="top" align="left" scope="col" rowspan="1" colspan="1">DRUG</th>
                <th id="hd_h_Pilocarpine.Tc_1_1_1_2" valign="top" align="left" scope="col" rowspan="1" colspan="1">CAS REGISTRY NO.</th>
                <th id="hd_h_Pilocarpine.Tc_1_1_1_3" valign="top" align="left" scope="col" rowspan="1" colspan="1">MOLECULAR FORMULA</th>
                <th id="hd_h_Pilocarpine.Tc_1_1_1_4" valign="top" align="left" scope="col" rowspan="1" colspan="1">STRUCTURE</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_Pilocarpine.Tc_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Pilocarpine</td>
                <td headers="hd_h_Pilocarpine.Tc_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pubchem" xlink:href="sid://134972029">92-13-7</ext-link>
                </td>
                <td headers="hd_h_Pilocarpine.Tc_1_1_1_3" valign="top" align="left" rowspan="1" colspan="1">C11-H16-N2-O2</td>
                <td headers="hd_h_Pilocarpine.Tc_1_1_1_4" valign="top" align="left" rowspan="1" colspan="1">
                  <related-object link-type="ext-image-back-link" source-id="pubchem" document-id="134972029" document-id-type="sid" document-type="summary" object-id="134972029" object-id-type="sid" object-type="image"/>
                </td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </sec>
      <sec id="Pilocarpine.ANNOTATED_BIBLIOGRAPHY">
        <title>ANNOTATED BIBLIOGRAPHY</title>
        <p>References updated: 24 June 2020</p>
        <ref-list id="Pilocarpine.ANNOTATED_BIBLIOGRAPHY.reflist0">
          <ref id="Pilocarpine.REF.zimmerman.1999">
            <mixed-citation publication-type="book">Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott, 1999.<annotation><p><italic toggle="yes">(Extensive review of hepatotoxicity published in 1999; cholinergic agents and pilocarpine are not discussed).</italic></p></annotation></mixed-citation>
          </ref>
          <ref id="Pilocarpine.REF.kaplowitz.2013">
            <mixed-citation publication-type="book">Kaplowitz N, DeLeve LD, eds. Drug-induced liver disease. 3rd ed. Amsterdam: Elsevier, 2013.<annotation><p><italic toggle="yes">(Textbook of hepatotoxicity published in 2013; cholinergic agents and pilocarpine are not discussed).</italic></p></annotation></mixed-citation>
          </ref>
          <ref id="Pilocarpine.REF.henderer.2018">
            <mixed-citation publication-type="book">Henderer JD, Rapuano CJ. Ocular pharmacology. In, Brunton LL, Hilal-Dandan R, Knollman BC, eds. Goodman &#x00026; Gilman's the pharmacological basis of therapeutics. 13th ed. New York: McGraw-Hill, 2018, pp. 1251-70.<annotation><p><italic toggle="yes">(Textbook of pharmacology and therapeutics).</italic></p></annotation></mixed-citation>
          </ref>
          <ref id="Pilocarpine.REF.fox.1986.243">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Fox</surname>
                  <given-names>PC</given-names>
                </name>
                <name name-style="western">
                  <surname>van der Ven</surname>
                  <given-names>PF</given-names>
                </name>
                <name name-style="western">
                  <surname>Baum</surname>
                  <given-names>BJ</given-names>
                </name>
                <name name-style="western">
                  <surname>Mandel</surname>
                  <given-names>ID</given-names>
                </name>
              </person-group>
              <article-title>Pilocarpine for the treatment of xerostomia associated with salivary gland dysfunction.</article-title>
              <source>Oral Surg Oral Med Oral Pathol</source>
              <year>1986</year>
              <volume>61</volume>
              <fpage>243</fpage>
              <lpage>8</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Pilot study of single doses of pilocarpine or placebo in 6 patients with Sj&#x000f6;gren syndrome demonstrated an increase in salivary flow and decrease in sensation of dry mouth).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">3517744</pub-id>
            </element-citation>
          </ref>
          <ref id="Pilocarpine.REF.rieke.1995.661">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Rieke</surname>
                  <given-names>JW</given-names>
                </name>
                <name name-style="western">
                  <surname>Hafermann</surname>
                  <given-names>MD</given-names>
                </name>
                <name name-style="western">
                  <surname>Johnson</surname>
                  <given-names>JT</given-names>
                </name>
                <name name-style="western">
                  <surname>LeVeque</surname>
                  <given-names>FG</given-names>
                </name>
                <name name-style="western">
                  <surname>Iwamoto</surname>
                  <given-names>R</given-names>
                </name>
                <name name-style="western">
                  <surname>Steiger</surname>
                  <given-names>BW</given-names>
                </name>
                <name name-style="western">
                  <surname>Muscoplat</surname>
                  <given-names>C</given-names>
                </name>
                <name name-style="western">
                  <surname>Gallagher</surname>
                  <given-names>SC</given-names>
                </name>
              </person-group>
              <article-title>Oral pilocarpine for radiation-induced xerostomia: integrated efficacy and safety results from two prospective randomized clinical trials.</article-title>
              <source>Int J Radiat Oncol Biol Phys</source>
              <year>1995</year>
              <volume>31</volume>
              <fpage>661</fpage>
              <lpage>9</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 369 patients with xerostomia following cancer radiotherapy who were treated with pilocarpine [2.5-10 mg every 8 hours] or placebo for 12 weeks, there were no serious drug related adverse events at any dose).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">7852133</pub-id>
            </element-citation>
          </ref>
          <ref id="Pilocarpine.REF.vivino.1999.174">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Vivino</surname>
                  <given-names>FB</given-names>
                </name>
                <name name-style="western">
                  <surname>Al-Hashimi</surname>
                  <given-names>I</given-names>
                </name>
                <name name-style="western">
                  <surname>Khan</surname>
                  <given-names>Z</given-names>
                </name>
                <name name-style="western">
                  <surname>LeVeque</surname>
                  <given-names>FG</given-names>
                </name>
                <name name-style="western">
                  <surname>Salisbury</surname>
                  <given-names>PL</given-names>
                  <suffix>3rd</suffix>
                </name>
                <name name-style="western">
                  <surname>Tran-Johnson</surname>
                  <given-names>TK</given-names>
                </name>
                <name name-style="western">
                  <surname>Muscoplat</surname>
                  <given-names>CC</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sj&#x000f6;gren syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial. P92-01 Study Group.</article-title>
              <source>Arch Intern Med</source>
              <year>1999</year>
              <volume>159</volume>
              <fpage>174</fpage>
              <lpage>81</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 373 patients with Sj&#x000f6;gren syndrome who were treated with pilocarpine [2.5 or 5 mg 4 times daily] or placebo for 12 weeks, none had serious drug related adverse events; liver function tests were monitored, but there was no mention of ALT elevations or hepatotoxicity).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">9927101</pub-id>
            </element-citation>
          </ref>
          <ref id="Pilocarpine.REF.wu.2006.796">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Wu</surname>
                  <given-names>CH</given-names>
                </name>
                <name name-style="western">
                  <surname>Hsieh</surname>
                  <given-names>SC</given-names>
                </name>
                <name name-style="western">
                  <surname>Lee</surname>
                  <given-names>KL</given-names>
                </name>
                <name name-style="western">
                  <surname>Li</surname>
                  <given-names>KJ</given-names>
                </name>
                <name name-style="western">
                  <surname>Lu</surname>
                  <given-names>MC</given-names>
                </name>
                <name name-style="western">
                  <surname>Yu</surname>
                  <given-names>CL</given-names>
                </name>
              </person-group>
              <article-title>Pilocarpine hydrochloride for the treatment of xerostomia in patients with Sj&#x000f6;gren syndrome in Taiwan--a double-blind, placebo-controlled trial.</article-title>
              <source>J Formos Med Assoc</source>
              <year>2006</year>
              <volume>105</volume>
              <fpage>796</fpage>
              <lpage>803</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 44 patients with Sj&#x000f6;gren syndrome treated with pilocarpine [5 mg 4 times daily] or placebo for 12 weeks, the most common side effect was excessive sweating [22%] and there were no serious adverse events or "significant alterations in ...hepatic profiles").</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">17000452</pub-id>
            </element-citation>
          </ref>
          <ref id="Pilocarpine.REF.fox.2003.247">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Fox</surname>
                  <given-names>RI</given-names>
                </name>
              </person-group>
              <article-title>Sjogren's syndrome: evolving therapies.</article-title>
              <source>Expert Opin Investig Drugs</source>
              <year>2003</year>
              <volume>12</volume>
              <fpage>247</fpage>
              <lpage>54</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Review of standard and experimental therapies of Sj&#x000f6;gren syndrome mentions pilocarpine and cevimeline, but does not discuss its adverse side effects).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">12556218</pub-id>
            </element-citation>
          </ref>
          <ref id="Pilocarpine.REF.papas.2004.169">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Papas</surname>
                  <given-names>AS</given-names>
                </name>
                <name name-style="western">
                  <surname>Sherrer</surname>
                  <given-names>YS</given-names>
                </name>
                <name name-style="western">
                  <surname>Charney</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Golden</surname>
                  <given-names>HE</given-names>
                </name>
                <name name-style="western">
                  <surname>Medsger</surname>
                  <given-names>TA</given-names>
                  <suffix>Jr</suffix>
                </name>
                <name name-style="western">
                  <surname>Walsh</surname>
                  <given-names>BT</given-names>
                </name>
                <name name-style="western">
                  <surname>Trivedi</surname>
                  <given-names>M</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Successful treatment of dry mouth and dry eye symptoms in Sj&#x000f6;gren syndrome patients with oral pilocarpine: a randomized, placebo-controlled, dose-adjustment study.</article-title>
              <source>J Clin Rheumatol</source>
              <year>2004</year>
              <volume>10</volume>
              <fpage>169</fpage>
              <lpage>77</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 250 patients with Sj&#x000f6;gren syndrome treated with pilocarpine [20-30 mg daily] or placebo for 12 weeks, there were no serious drug related adverse events or significant changes in laboratory results in comparison to placebo).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">17043506</pub-id>
            </element-citation>
          </ref>
          <ref id="Pilocarpine.REF.berk.2008.1333">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Berk</surname>
                  <given-names>L.</given-names>
                </name>
              </person-group>
              <article-title>Systemic pilocarpine for treatment of xerostomia.</article-title>
              <source>Expert Opin Drug Metab Toxicol</source>
              <year>2008</year>
              <volume>4</volume>
              <fpage>1333</fpage>
              <lpage>40</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Review of 6 controlled trials of pilocarpine for radiation induced xerostomia; among 261 patients treated long term, side effects included sweating [55%], urinary frequency [11%], rhinitis [10%], headache [8%], increased lacrimation [8%] and diarrhea [6%], with no mention of ALT elevations or clinically apparent liver injury).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">18798702</pub-id>
            </element-citation>
          </ref>
          <ref id="Pilocarpine.REF.ramoscasals.2010.452">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Ramos-Casals</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Tzioufas</surname>
                  <given-names>AG</given-names>
                </name>
                <name name-style="western">
                  <surname>Stone</surname>
                  <given-names>JH</given-names>
                </name>
                <name name-style="western">
                  <surname>Sis&#x000f3; Bosch</surname>
                  <given-names>X</given-names>
                </name>
              </person-group>
              <article-title>Treatment of primary Sj&#x000f6;gren syndrome: a systematic review.</article-title>
              <source>JAMA</source>
              <year>2010</year>
              <volume>304</volume>
              <fpage>452</fpage>
              <lpage>60</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Review of 3 controlled trials of pilocarpine in 673 patients with Sj&#x000f6;gren syndrome found improvements in symptoms of dry mouth and dry eyes with a dose of 5 mg every 6 hours, but also a higher rate of excessive sweating, urinary frequency and nausea; no mention of ALT elevations or clinically apparent liver injury).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">20664046</pub-id>
            </element-citation>
          </ref>
          <ref id="Pilocarpine.REF.reuben.2010.2065">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Reuben</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Koch</surname>
                  <given-names>DG</given-names>
                </name>
                <name name-style="western">
                  <surname>Lee</surname>
                  <given-names>WM</given-names>
                </name>
                <collab>Acute Liver Failure Study Group</collab>
              </person-group>
              <article-title>Drug-induced acute liver failure: results of a U.S. multicenter, prospective study.</article-title>
              <source>Hepatology</source>
              <year>2010</year>
              <volume>52</volume>
              <fpage>2065</fpage>
              <lpage>76</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 1198 patients with acute liver failure enrolled in a US prospective study between 1998 and 2007, 133 were attributed to drug induced liver injury, but none were linked to pilocarpine or other cholinergic agents).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">20949552</pub-id>
            </element-citation>
          </ref>
          <ref id="Pilocarpine.REF.chalasani.2015.1340">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Chalasani</surname>
                  <given-names>N</given-names>
                </name>
                <name name-style="western">
                  <surname>Bonkovsky</surname>
                  <given-names>HL</given-names>
                </name>
                <name name-style="western">
                  <surname>Fontana</surname>
                  <given-names>R</given-names>
                </name>
                <name name-style="western">
                  <surname>Lee</surname>
                  <given-names>W</given-names>
                </name>
                <name name-style="western">
                  <surname>Stolz</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Talwalkar</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>Reddy</surname>
                  <given-names>KR</given-names>
                </name>
                <etal/>
                <collab>United States Drug Induced Liver Injury Network</collab>
              </person-group>
              <article-title>Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study.</article-title>
              <source>Gastroenterology</source>
              <year>2015</year>
              <volume>148</volume>
              <fpage>1340</fpage>
              <lpage>1352.e7</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 899 cases of drug induced liver injury enrolled in a US prospective study between 2004 and 2013, no cases were attributed to pilocarpine or other cholinergic agents).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">25754159</pub-id>
            </element-citation>
          </ref>
          <ref id="Pilocarpine.REF.tanigawa.2015.164">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Tanigawa</surname>
                  <given-names>T</given-names>
                </name>
                <name name-style="western">
                  <surname>Yamashita</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>Sato</surname>
                  <given-names>T</given-names>
                </name>
                <name name-style="western">
                  <surname>Shinohara</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Shibata</surname>
                  <given-names>R</given-names>
                </name>
                <name name-style="western">
                  <surname>Ueda</surname>
                  <given-names>H</given-names>
                </name>
                <name name-style="western">
                  <surname>Sasaki</surname>
                  <given-names>H</given-names>
                </name>
              </person-group>
              <article-title>Efficacy and safety of pilocarpine mouthwash in elderly patients with xerostomia.</article-title>
              <source>Spec Care Dentist</source>
              <year>2015</year>
              <volume>35</volume>
              <fpage>164</fpage>
              <lpage>9</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 40 elderly patients with dry mouth who were treated with pilocarpine or plain water mouthwash for 4 weeks, drop outs were frequent, and common side effects were oral or tongue discomfort, while xerostomia improved with the pilocarpine but not the water mouthwash).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">25639487</pub-id>
            </element-citation>
          </ref>
          <ref id="Pilocarpine.REF.britozer_n.2019.e001064">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Brito-Zer&#x000f3;n</surname>
                  <given-names>P</given-names>
                </name>
                <name name-style="western">
                  <surname>Retamozo</surname>
                  <given-names>S</given-names>
                </name>
                <name name-style="western">
                  <surname>Kostov</surname>
                  <given-names>B</given-names>
                </name>
                <name name-style="western">
                  <surname>Baldini</surname>
                  <given-names>C</given-names>
                </name>
                <name name-style="western">
                  <surname>Bootsma</surname>
                  <given-names>H</given-names>
                </name>
                <name name-style="western">
                  <surname>De Vita</surname>
                  <given-names>S</given-names>
                </name>
                <name name-style="western">
                  <surname>D&#x000f6;rner</surname>
                  <given-names>T</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Efficacy and safety of topical and systemic medications: a systematic literature review informing the EULAR recommendations for the management of Sj&#x000f6;gren's syndrome.</article-title>
              <source>RMD Open</source>
              <year>2019</year>
              <volume>5</volume>
              <elocation-id>e001064</elocation-id>
              <annotation>
                <p>
                  <italic toggle="yes">(Systematic review of the literature on therapies for sicca syndrome mentions 5 controlled trials showing improvements in oral dryness and saliva flow with pilocarpine and cevimeline but no evidence for effects from trials of systemic treatments with anakinra, hydroxychloroquine, infliximab or rituximab).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">31749986</pub-id>
            </element-citation>
          </ref>
        </ref-list>
      </sec>
      <sec sec-type="link-group" id="Pilocarpine.OTHER_REFERENCE_LINKS">
        <title>OTHER REFERENCE LINKS</title>
        <list list-type="order">
          <list-item>
            <label>1</label>
            <p>
              <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&#x00026;db=pubmed&#x00026;pubmedfilters=true&#x00026;term=Pilocarpine+AND+Human%5BMH%5D+AND+(drug+induced+liver+injury+OR+jaundice/CI+OR+bile+duct+diseases/CI+OR+liver/DE+OR+liver+diseases/CI)+AND+(%221900/1/1%22%5BEDat%5D:%222999/12/31%22%5BEDat%5D)">Recent References on Pilocarpine: from PubMed.gov</ext-link>
            </p>
          </list-item>
          <list-item>
            <label>2</label>
            <p>
              <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/results?term=Pilocarpine">Trials on Pilocarpine: from ClinicalTrials.gov</ext-link>
            </p>
          </list-item>
        </list>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
